04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
17:40 , Dec 11, 2018 |  BC Innovations  |  Translation in Brief

Diseased oligodendrocytes

A Karolinska Institute team has identified subsets of oligodendrocyte lineage cells that may trigger T cell immunity in multiple sclerosis and proposed the cells as new disease targets. The findings suggest the myelin-producing cells are...
22:56 , Dec 5, 2018 |  BC Extra  |  Tools & Techniques

Proteogenomic screen identifies non-mutated tumor-specific antigens

A University of Montreal team has developed a proteogenomic screen that identifies mutated and non-mutated tumor-specific TCR antigens, including those arising from normally non-coding nucleotide sequences. The technique could help develop T cell immunotherapies targeting...
13:09 , Dec 4, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug platforms

TECHNOLOGY: Cellular assays; cell therapies A sequencing-based method of identifying neoantigen-specific TCRs could be used to develop personalized T cell therapies for cancer. The method involves six steps: using in vitro transcription and translation techniques...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
23:00 , Nov 12, 2018 |  BC Extra  |  Preclinical News

Sequencing-based method identifies neoantigen-specific TCRs

In a Nature Biotechnology paper , researchers described a method to identify TCRs that bind to specific neoantigens, which could enable efficient and inexpensive production of personalized T cell therapies. The high-throughput technique, developed by...
18:33 , Oct 19, 2018 |  BC Week In Review  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
14:41 , Oct 15, 2018 |  BC Extra  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...